Kaleido news
4 March 2020

FIELD SAFETY NOTICE Kaleido insulin cartridge destruction

March 4th, 2020. Important safety notice about our Kaleido insulin cartridge.

Kaleido is available in the Netherlands. After a successful start and a bumpy growth period, it was decided on 4th March 2020 to pause the distribution and use of Kaleido to further develop the product and organization. The last three years have been spent working on a new production site, building a professional team and compiling a comprehensive evaluation of the user experience, based on over 500,000 hours of wear. As of March 2023, the Kaleido Insulin Pump System is once again available in the Netherlands.

In recent years, the production process has been adapted to accommodate thousands of users, with a focus on consistent quality. We have improved quality systems, reviewed collaborations with suppliers and optimized every element of Kaleido. We have moved to a new production site with a brand new, larger cleanroom, and we also founded a user group in the Netherlands called the K- Force. This group has provided us with invaluable user experience insights on both the product and the service we provide. The feedback from this process has given us the confidence to make Kaleido available to a wider audience across the Netherlands.

Any person based in the Netherlands, with the support of their healthcare professional, can now use Kaleido again. As for other countries, we’ll soon be available in Germany! If you would like here more about this, please call Kaleido Care directly on 0800-1910.

Unfortunately, due to an issue with one of our key suppliers, there is a risk of the tubing detaching from our Kaleido insulin cartridge. This can lead to reduced or no insulin delivery. We put the safety of our customers first and have deemed the risk too high. Therefore, our customers have to stop using our cartridges immediately and destroy the supply they still have.

It is unclear how long it will take to re-supply our customers. We advise our active customers to seek another form of insulin therapy. Healthcare providers have been informed of this issue. We are working with them to support our customers in their switch to a different form of insulin therapy.

We are aware of the huge impact this has on our Kaleidoers, but we have a responsibility to put their safety first. And we know the impact of diabetes on daily life can be demanding and the last thing we want is to make that worse.

If customers have any questions, they can reach out to Kaleido Care at +44 (0) 808 189 21 46. They can also send an email to hello@hellokaleido.com.

Last update: 29-05-2023